Quarterly review: Changes to recommendations in Prime Funds & Prime ETFs

Prime Funds is our list of recommendations in equity, debt, and hybrid mutual funds that are worth investing in. Prime Funds narrows down your choices from the thousands of funds that there are, into a concise list of funds that span different styles. Prime Funds are selected based on performance, portfolios, and investment strategies. 

In this quarter’s review, we have added to equity funds to play themes that are ripe and made changes to the hybrid recommendations to include better return options. We have made minimal changes to our debt fund recommendations. 

Quarterly review - Changes to recommendations in Prime Funds and Prime ETFs

If you are new to Prime Funds, do read the section on ‘About Prime Funds’ to know how to use them to your advantage. Otherwise, use the Table of Contents below to navigate to the section of your interest.

About Prime Funds

Prime Funds is our list of best mutual funds across the equity, debt, and hybrid categories. We use Prime Ratings, our fund ratings, as a first filter. We then apply qualitative analysis to arrive at our fund recommendations. Prime Funds is an enduring list of funds that you can use at any time. You will always find a fund to meet any goal you’re looking to meet.

Different categories: Prime Funds are separated into buckets, based on risk level in equity & hybrid funds and timeframe in debt funds. Each of these draws from different SEBI-defined categories. We have classified them in a more user-friendly way than using the several dozens of SEBI categories. We do not go only by Prime Ratings but look at other factors as well to narrow the list and make the choices easy for you.

Different styles: In Prime Funds, we’ve aimed at providing funds that follow different strategies for you to mix styles and diversify your portfolio with ease. The ‘Why this fund’ for each Prime Fund will brief its strategy, why we picked it, and how to use it in your portfolio.

Direct plans: We have specifically given the direct plans in Prime Funds. If you wish to know whether it is ok for you to use the regular plan of the fund, check our MF Review Tool (not our Ratings). If the review specifies ‘buy through direct,’ it means that the expense ratio differential is high under the regular plan for that fund. You will be better off using the direct plan in such cases. You can also check the expense ratio differential using our expense ratio tool.

Quarterly review: Our aim in reviewing the Prime Funds list every quarter is to ensure that we don’t miss any good opportunities that are coming up and we are not holding on to funds that are slipping. When we remove funds from the Prime Funds list, we tell you exactly what to do if you have invested in these funds. Funds we remove do not immediately call for a sell – it is just that they have slipped in performance marginally or there are better alternatives now. Unless our review tool says such funds are a ‘sell’, you can hold them (refer to our article on when to sell funds)

Using Prime Funds: You don’t need to hold every Prime Fund nor add any new fund we introduce to the list. Unless it fits your overall portfolio/strategy, or there is something lacking, there is little need for you to go on adding funds. Our idea of covering them in detail through some of our weekly calls is to let you know the strategy, style, and suitability in different portfolios. It is not a specific call to buy right away, unless we mention that it is a ‘tactical’ or ‘timing’ call.

Equity funds

The Nifty 50 and Sensex made merry in the December 2022 quarter, notching up new peaks. But the mid-cap and small-cap segments still had some struggle and small-caps are yet to reach their own earlier peaks. As we explained in our Prime Funds 2022 performance review recently, funds that held true to a buy-and-hold strategy found it harder to hold up in the sideways markets we have seen for much of this year. This apart, funds that followed a more growth-oriented strategy also saw poorer performance as value came to the fore.

Our changes in equity Prime Funds over the past few quarters have been aimed at curbing underperformance where it was stark and identifying up-and-coming funds early. To this extent, our equity fund recommendations have held up well. The changes we’re making to the recommendations are minimal. We have, however, explained the underperformance in some of the funds and which we are watching for improvement. 

Equity – Moderate (Active and Passive)

In this set of Prime Funds, we have removed ICICI Prudential Nifty 100 Low Volatility 30 ETF FoF that comes under the Passive category. We chose this as the index had showcased the ability to both deliver long-term returns and protect downsides. The Nifty 100 Low Vol 30 has served the purpose of containing downsides; its monthly downside capture ratio holds up well. However, the index has been returning far lower than the Nifty 100 (a limitation in factor-based indices is that historical levels that are calculated and provided prior to the index’s actual launch are often theoretical to fit the factors chosen. Real-time performance can differ). 

On a rolling 1-year basis, the return differential between the Nifty 100 and the Nifty Low Vol 30 has gone up to even 10 percentage points at times in past 2 years. The stark differential has also impacted the longer-term returns as well, with the two indices very similar in returns. In the absence of healthy returns, there is limited purpose that the Low Vol index may serve. 

Continue to hold investments made so far in the ICICI Pru Nifty 100 Low Vol 30 FoF, if you have any. It can retain its purpose of protecting downsides. However, avoid making further investments in the fund and increasing exposure. For any SIPs, you can divert the amount to an index fund tracking the Nifty 50 or the Nifty 100, or even in active funds that score on downside containment and low volatility.

There are no other changes we are making in the Equity – Moderate Prime Funds set. However, we’d like to explain the performance of two funds as below. Please note that the funds remain part of the recommendation. We will alert you if any action is required.

  • Canara Robeco Flexicap fund has been trailing the Nifty 500 TRI for the past couple of quarters. The margin of underperformance is not very deep ranging at about 2-4 percentage points. The fund’s growth-oriented investment style has pinched returns as value came to the fore. That saw the fund be underweight on some sectors and stocks that outperformed. For example, while the fund had a heavy banking weight, it held more in stocks such as HDFC Bank that were underperformers. It did not hold as much in capital goods, auto, cement, or realty all of which were outperforming sectors. Its IT and chemicals picks hurt, while its consumer picks are only just looking up. We are not too worried about the fund’s performance at this time. We are watching performance and will take a call if necessary.
  • Parag Parikh Flexi Cap buckled under the pressure faced by its US stock exposure. That exposure has come down to 15% of the portfolio now from 29% in January 2022 on account of stock price correction; the fund has used the correction to average in these stocks. The domestic portfolio is holding up well and its value tilt can continue to see it perform. We have explained the fund in more detail earlier. The fund remains part of our list.

Equity – Aggressive (Active and Passive)

In this Prime Funds category, we have removed UTI Flexicap from the list. We had noted its underperformance in the previous review but had retained it stemmed from some contrarian calls. However, the depth of underperformance has worsened over the past quarter and the fund now trails the Nifty 500 TRI by about 14-15 percentage points on a rolling 1-year return basis. Apart from a higher holding in IT stocks that weighed, the fund was also underweight on outperforming sectors such as auto and financials. The fund does have exposure to sectors and stocks with potential such as cement, niche IT, capital goods and consumption. However, without signs of performance improvement, it is best to stop further investments in the fund. Stop SIPs if running and retain all investments made so far.

We have also removed Union Small Cap from the list. This is not due to performance. The fund’s manager Vinay Paharia, who was instrumental in its turnaround, has resigned. The investment processes he put in place continue to hold and the current fund manager was co-managing the fund earlier. However, we wish to be cautious on the fund given the category, the fund’s smaller size, and the role Mr Paharia played in its performance improvement. Stop SIPs if running and retain all investments made so far.

In the Passive section of this Prime Funds category, we are adding Motilal Oswal S&P 500 index fund. This index fund tracks the S&P 500 index, a US market index that represents the 500 largest and most liquid US stocks. The index is a major US market index and is more diversified and less tech-heavy than the Nasdaq 100 index. This index fund was earlier part of Prime Funds, which we removed last January due to RBI’s restrictions on funds investing internationally and funds closing off fresh subscriptions in consequence. As this fund is now accepting fresh inflows, we are adding it back. It can be used by those looking to diversify their portfolio overseas. 

There are no other changes we are making in the Equity – Aggressive Prime Funds set. However, we’d like to explain the performance of two funds as below. Please note that the funds remain part of the recommendation. We will alert you if any action is required.

  • PGIM Flexicap is currently trailing the Nifty 500 TRI. This is a fund we added for its ability to churn portfolios to play different themes. The fund is a tad more aggressive with a higher mid-cap and small-cap allocation, which has hurt recent returns. This apart, some focused exposures such as Infosys, HDFC Bank, CAMS, as well as smaller holdings in other stocks hurt. However, the fund’s strategy of quick churn and identifying performers continues to hold good and it has made several timely entry, book profit, and exit calls. Its long-term returns are also well above peers and index.
  • SBI Focused Equity has fallen behind the Nifty TRI in 1-year returns which has marginally spilled over into 3-year returns. For focused funds, a bigger underperformance is not surprising owing to the concentrated stock holdings which amplifies the impact of calls going wrong. In this fund, the top bets of Reliance Industries, HDFC and Infosys have all served to stymie returns. It also follows a buy-and-hold strategy which has taken a backseat in this shifting market. the fund’s portfolio is otherwise made up of sound stocks that tap into a very wide range of opportunities. Given the category and strategy, some underperformance is to be expected. The fund has gone through bouts of poor performance earlier as well and emerged strong. We are watching performance and will take a call if performance further deteriorates.

Equity – Strategy & Thematic

We are increasingly of the view that adding some thematic funds, if one can time them reasonably, will help generate alpha better than going with just an all-diversified fund portfolio. This view stems from the steadily growing challenges for regular active equity funds to beat their benchmark in recent years. We highlighted in our Prime Funds Review for 2022 on how both the thematic funds we added in 2022 delivered well as their entry was timely. This year too, we would like to focus on such tactical entry points. Towards this, we have made some changes to this category.

We have removed Invesco India Infrastructure that we added in 2021. While the timing of this call was right and it beat the market over the past 6 months, the fund has underperformed peers due to stock holdings that looked sound but did not participate in the ensuing rally. We now want to focus only on specific segments to play the core sector recovery and are therefore removing it. You can exit whenever your exposure (as a proportion of your portfolio) goes 3-4 percentage points more than where you started. 

We have removed Tata Digital. We remain positive about the IT sector, as a contrarian pick. We already have one fund to play this space and are therefore removing this fund to reduce the duplication and make the list more concise. Continue to hold this fund if you are already invested, as its prospects remain good.

We have added Motilal Oswal Nifty Bank Index to add to our already existing active fund from the banking & financial services sectors. For those of you who want to hug the bank index (which continues to outperform Nifty from 2022), this will be a passive route. Thus far, only ETFs were available to play this index. With this, you can go passive. The fund is best bought on market falls (invest on dips). You don’t need this fund if you already holding a banking fund. The banking sector has already rallied well and entry points have to be only on market dips.

We are once again adding ICICI Prudential Commodities. We had given a book profit call on the fund in mid-2022, and asked you to retain the remaining holding in the fund. Therefore, if you hold the fund, continue to do so. This fund is playing the core sector recovery through cement and steel. In our view, the cement sector is undergoing consolidation and a clear recovery. In steel, prospects for local steel demand remain elevated even as global prices may have cooled from their peak.  We expect this fund together with banking funds, manufacturing fund and the transportation fund (the last 2 we already have in the list), to benefit from the core sector recovery.

Hybrid funds

Considering that markets may remain volatile for some time, we have focused on adding hybrid funds that can reduce any fall and deliver equity-linked returns.

Hybrid – Moderate Risk

We have added Quant Absolute, a risky hybrid fund with two-thirds in equity and rest in debt. This fund, similar to funds from the same AMC, takes tactical calls, churning its portfolio often in the process. In debt, though, the fund sticks to safe options such as government securities, deposits and treasury bills. The fund has beat its category convincingly over 1 and 3-year rolling return periods. It will however remain volatile (going by its high standard deviation) and is suitable for high-risk investors.

We have added another differentiated fund - ICICI Pru Multi-Asset Fund. This addition is from the multi asset allocation category, one that we usually avoid. We made the exception in this case as ICICI Pru Multi-Asset not only invests in the usual equity debt and gold asset classes that multi asset funds do, but also chooses commodities such as silver and oil futures, to play tactically. Besides, the fund uses derivatives both in equity (for arbitrage) as well interest rate swaps (in debt). This both contains downside as well as helps add to returns. This ability to go anywhere there is return potential makes it useful to counter poor equity performance in years of market consolidation.

If you leave out Quant Multi Asset, which makes more short-term equity calls to generate returns, ICICI Pru Multi-Asset convincingly beats all other peers and measures up quite well even with the equity hybrid fund category. Treat this fund as part of your moderate risk allocation. Do not try to use it as a one-fund-for-all-asset classes option. It is simply another hybrid fund that can help returns during market consolidation and counter equity risk. The fund tends to have an equity orientation for tax purposes.

We have removed Mirae Asset Hybrid Equity from this category. This fund has seen underperformance since early 2022 but has narrowed it later in the year. Still, its growth-oriented approach (as with other Mirae funds) may see some underperformance in 2023 too, as value continues to gain traction in the market.  We continue to have a ‘buy’ on Mirae Asset Hybrid Equity in our MF Review Tool. You can hold investments made as well as continue existing SIPs. We removed the fund also because we already have two aggressive hybrid funds in the set and we’d like to keep the list concise and make space for the two differentiated funds we added here.

Hybrid – Low Risk

In this category, we removed DSP Dynamic Asset Allocation - one of our trusted funds from the balanced advantage/dynamic asset allocation category. This fund continues firmly on the side of conservatism with low net equity and its risk-adjusted returns remained high. However, it has now slipped over the past 2 quarters and has delivered lower than arbitrage funds in the past year. These comparative lower returns make it less attractive at this time. You can continue to hold this fund for tax efficiency and as a hedge to your equity portfolio. Fresh investments can be done in other funds from our list. The other funds in this set - arbitrage and equity savings (in that order) - will continue to serve the purpose of low risk in equity. 

Debt funds

After reacting negatively to a series of interest rate hikes in 2022, bond markets have taken a breather. Our Prime debt outlook (2023) details what we expect in 2023 and how to go about investing. Our debt funds are fully game to take on moderate rate hikes and flat periods (provided you choose the right bucket of funds for your purposes). While shorter duration yields have moved up pretty quickly, there is also opportunity in the longer duration space if rates begin to fall in the later part of the year or in 2024. Towards this, we have added a fund from the short duration category with high yield but with a higher duration as well.

Debt – Medium term

We have added ICICI Pru Short Term Fund in this Prime Funds set, where we usually house medium duration or corporate bond funds. This fund’s current portfolio YTM is 7.76%. It has well over a third in G-Secs but 12% of such exposure is to floating rate G-Secs. As a result, despite an average maturity of 5.2 years, its modified duration is much lower at 1.5 years. This fund can give the advantage of high yields if rates remain high and also help participate to some extent in any price rally when rates fall. We have added the fund to the medium-term space owing to its higher maturity profile. You will accordingly need the time frame we have specified for this category if you wish to invest in this fund. You don’t need to switch any existing corporate bond funds just for the sake of entering this fund now. 

Prime ETFs

Prime ETFs is our list of recommended ETFs in equity, debt, and gold. We look at multiple factors to draw up this list, ranging from short-term and long-term tracking error, expense ratio, trading volumes and usefulness of the index in a portfolio. In this review, we have made very few changes.

Moderate Risk

We removed ICICI Prudential Nifty 100 Low Volatility 30 ETF under the equity-moderate risk category. This ETF is still good at containing downside but has struggled to beat the parent index meaningfully. You will find more details earlier in this report where we have mentioned the FoF of this index from the same AMC. You can continue to hold the ETF as an option to contain market falls but avoid any fresh investments for long term. You will be better off with a Nifty 50 or Nifty 100 ETF or index fund.

Strategic and thematic

We have removed Kotak Nifty Bank ETF owing to marginally higher market price and NAV deviation compared with Nippon Bank BeES. You can continue to hold this ETF if you own it; do not exit. 

We have added Nippon India Nifty Pharma ETF. This ETF mirrors the Nifty Pharma index, which houses the 20 largest pharma stocks by free float market cap. This is a highly concentrated index with top 3 constituents accounting for over 50%. Pharma as a sector has gained traction as pharma companies have moved from doing just contract manufacturing to taking on end-to-end solutions from research to implementation to manufacturing. While the sector receives lower weight in the bellwether index compared with larger sectors such as banking and IT, it has been gaining ground post Covid with increased focus on medical research. The pharma index underperformed the market in 2022 but this has helped valuation settle to reasonable levels. This ETF is suitable only for long-term investors with a high risk appetite and the ability to take volatility. Mix this thematic ETF along with market-cap based index ETFs.

You can view the full Prime Funds list here.

You can view the full Prime ETFs list here.

More like this

24 thoughts on “Quarterly review: Changes to recommendations in Prime Funds & Prime ETFs”

  1. Icici pru has recommended to follow accrual strategy and has recommended UST, medium term, credit risk and all seasons bond fund. What is your view on that?

    1. Essentially the fund has asked to you buy all their funds 🙂 Please use our review tool to check buy or hold or sell on the said funds. Our debt outlook will be out soon. That will provide direction. thanks, Vidya

  2. Thanks for the review. I have 2 questions

    1) With many funds moving to hold, won’t the total number of funds and expense paid for the fund increase with time? Is it okay to hold so many funds in the portfolio?
    2) When do we start adding ICICI Pru Nifty IT ETF? With IT sector facing headwinds is this a good time to start accumulating ETF units?

    1. Sir,
      1. your expense ratio is proportionate to the total assets you hold. not the total funds. With time, of course, you can and should reduce funds. We have also addressed that in many articles.
      2. Yes you should and add on dips.
      Vidya

  3. Hi Team,

    Have stopped SIP in SBI Focused Equity and Holding this. Any Advice?

    Thanks, Vijay

    1. SBI Focused remains part of the Prime Funds list. We have also not given stop SIP recommendations. We have only mentioned reasons for recent underperformance in the report. Please remain invested. – thanks, Bhavana

  4. I guess most the funds you have recommended and i have invested are in either watch list or sell. I am thinking whether it was a right decision to take Prime Investor subscription. You guys are changing recommendations every now and then. Sell is not just sell right as you know it has implication of exit load, capital gains etc. I know that no one can predict the future but at least to some extent you guys should be able to do based on the analysis and data, that is what we are paying you for right.

    My Investment list
    SBI focused equity – Watch list
    Parag Parikh Flexi Cap – Watch list?
    Axis Mid – Hold
    Axis Small – Hold
    Axis Bluechip – Hold

    1. We understand your concerns. Let us clarify a bit. SBI Focused and Parag Parikh Flexicap are not on watch list. We have explained the reasons for the funds’ underperformance as there may be many of you who are concerned about returns not measuring up. We separately field queries from customers on our recommended fund performance, so our intention in these quarterly reviews is to explain performance of some funds where it may be worrying.

      As far as the Axis funds go, that call was driven primarily due to the front-running charges that the AMC has faced. It was a decision we made at the time as we had to balance the potential risks (regulatory/legal/redemption pressures etc) with the information available and we very consciously erred on the side of conservatism there. The funds have also turned underperformers.

      Please note that hold calls are not sells. Funds we remove from the list are also not sells unless we explicitly mention it as such. – thanks, Bhavana

      (Edited for clarity)

  5. Vittal Venugopal

    Hello Team Primeinvestor,

    Thank you for the quarterly updated review. It is really useful review to take stock of things. I was looking for a similar product like ICICI Pru MultiAsset Fund . Is this fund considered as equity or debt product for taxation purpose?

    Do you have any view on ICICI Pru Passive MultiAsset FOF? I see they have lot of ETF’s and also foreign ETF’s bundled into one product. I would appreciate your comments on the above fund. Thanks

    1. Vittal Venugopal

      Have you considered the expense ratio of ICICI Pru Multi Asset Fund? It is a bit high at 1.16 %.

      1. The category in general has higher expense ratios given the nature of management involved. It’s not alarming, and the fund is a good performer in the category and has deftly changed its portfolio to cover different asset opportunities. – thanks, Bhavana

    2. Based on portfolio trends, the I Pru Multi Asset fund has been equity-oriented for tax purposes.

      The passive FoF will have limited use. You can well hold individual passive funds/ETFs and allocate weights based on your timeframe and risk. If at all, this fund can at best be treated like the multi-asset fund above, as another hybrid diversifier to a portfolio. It can’t be taken as a fund to address asset allocation changes in your overall portfolio. – thanks, Bhavana

  6. Please correct me if I’m wrong but I’m starting to be a little concerned with so much churn in Prime Funds recommendations. A lot of active funds can routinely underperform and I think it’s useful to distinguish between structural underperformance and cyclical underperformance.

    Most of the funds that I chose from the Prime Funds list have been removed – Axis Smallcap, DSP Midcap, ICICI Low Vol ETF and DSP Dynamic Asset allocation fund. What is the use of holding active funds if we keep churning the portfolio so frequently? We are then essentially buying high and selling low. I think there is enough acceptance in the investment community that one needs to hold active funds for a long enough period to tide over occassional underperformance.

    Here is a more fundamental question. We want fund managers to have a long term mindset, then why do we have such a short term mindset while evaluating funds? Would it be better to be more patient and have a more qualititative approach towards evaluating fund performance?

    1. Here is another question. When we recommend investors to have at least a 3 year horizon (ideally 5) when investing in equity funds, why do we ourselves look at 1 year rolling returns to judge performance?

      1. Sir – rolling 1 year returns over 3 years (so essentially 4 years) is a extremely good way to understand fund turnarounds (both improving and falling). This will never come up in 3 years. hence, we use both rolling 1 year over 3 years (time period of 4 years essentially) and rolling 3-year return over 3 years (6 year period essentially)to assess the key metrics. And this has shown better signals than using only longer period of 3 year and 5 year.
        Vidya

    2. Hi Kanishk,

      Our endeavour is never to churn portfolio and we gain nothing by doing so. A few things will help aclrify.
      1. First, It will help to know the primary purpose of Prime Funds. it is to showcase the list of worthy funds TODAY. That is all that it will do. The funds removed are not sells and will continued to be monitored through the MF review tool. You should use it to see if the funds remain in hold and more often than not they will. If we do not remove the steady underperformers, we will never be able to add new funds that show promise. You will appreciate none of these funds are a ‘SELL’.
      2. Also, it will be worthwhile to know that we are NOT portfolio managers. We provide tools for you to do it. Our job is to identify funds that are undergoing a shift – either because the fund’s calls failed and underperformance is huge to fill the gap or the market is structurally shifting (from growth to value..which happened now). Then there will be outlier cases like Axis Smallcap where we were forced to give a call despite outperformance due to regulatory issues.
      3. Experience tells us that the margin of underperformance when it widens to double digits, will make comeback very difficult.
      We want fund managers to perform at least in line with index 🙂 That is their mandate right? If the market delivers 8% and a fund manager fails to deliver even that – there is no reason for you to be paying a fund management fee. Index fund should do right? Let’s not lose sight of this.

      On cyclical dips – of course we make that distinction. We waited for contra funds to perform when quality outperformed. Now contra is outperforming and we added more with value to ride it. This is necessary in any active management. Otherwise, it is easier to stick to passive funds – which we do encourage.
      the current market moves are not like earlier – there are too many factors influencing and fund managers cannot get easy signals. This is the reason why some fund houses that take tactical calls are outperforming now, not for a year or two but for 3-5 years now continuously. So we cannot lose sight of it. Performance is always RELATIVE. When that relative performance gap is too high – for several quarters in a row, that is when we actually take a call to even move a fund to a ‘hold’. A sell call is a last resort and is seldom given easily.

      thanks
      Vidya

      1. Vittal Venugopal

        Dear Vidya,
        Thank you very much for the detailed explaination. I fully agree with your views that it is better to dynamically manage MF portfolio’s. I used to earlier follow buy a fund and keep adding SIP. It ended up underperforming the respective index. Last 3-4 years returns has been better since I have started reshuffling funds/ stocks not doing well for long time compared to it’s peers. Unfortunately the buy and hold statergy is not working these days. Please continue to reshuffle the recommend MF and stocks which are under performing as per your criteria. 🙂

      2. Thank you for your detailed response. I’ll share my perspective of why this concerns me.

        I personally have my own conviction in two funds in my long term MF portfolio (Parag Parikh Flexicap and Kotak Nasdaq 100 etc). I have been relying on PrimeInvestor to provide me with research on which funds I can choose in some other categories (mid cap, small cap, smart beta etc) hoping that I wouldn’t need to change those funds too often.

        The main concern from my side is that a “HOLD” recommendation from PrimeInvestor’s side doesn’t help from a perspective of a customer who is doing regular SIPs. Most of us keep are salaried and we rely on regular cashflow to make additional regular investments in mutual funds. If I have 6 funds in my portfolio and 4 of them are Prime Fund recommendations, and if all those 4 get marked as “Hold”, I need to then find other funds in the same category for fresh investments. This adds unnecessary portfolio bloat.

        > Our endeavour is never to churn portfolio and we gain nothing by doing so

        I understand that. My argument is that it also doesn’t help your customers who make regular investments (using the SIP route) and rely on Prime Fund recommendations.

        It would be great if you can share data on what % of funds have stayed as Prime Funds and “Buy” recommendations since it’s inception? If that number is lesser than 30%, then the odds of a customer finding a decent fund that they can continue to SIP in for the long term become extremely low.

        As a long term investor, I’m personally not interested in insights on short term outperformance / underperformance. So, it may be worth considering this as another benefit which PrimeInvestor can provide. Maybe, a list of funds that have performed well over a long term period, have sound methodology and for which BUY/HOLD recommendations don’t change that often.

        1. Over 60-65% have stayed since launch. It is not as bad as you seem to think. There will definitely not be a coffee can portfolio in active funds. Yes we do have a great list of buy recommendations and we encourage investors to go for it when they write to us with the problem that you legitimately have. Those are passive funds 🙂 We think investors should give it a serious though. thanks, Vidya

  7. ICICI Pru Multi-Asset Fund is a welcome addition , Has been a good performer on returns as well as protected downsides well

Comments are closed.

Hold On

You are being redirected to another page,
it may take a few seconds.
Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

Start registration

Start registration

OR
user icon
user icon
user icon

Terms & Conditions

A copy of the T&C has been sent to your email.

Last modified on February 18, 2025

This website www.primeinvestor.in (“Website”) is owned and operated by PrimeInvestor Financial Research Pvt. Ltd. (“RA”), a SEBI-registered Research Analyst with Registration No. INH200008653.

Through the Website, the RA allows clients to access research recommendations, research reports, and model portfolios, along with tools, personal finance products, and articles, on the payment of a subscription fee (“Research Services”). The terms ‘RA’ or ‘us’ or ‘we’ refer to PrimeInvestor Financial Research Pvt Ltd (SEBI RA Registration No INH200008653) who are the owners of this Website and offering the Research Services. The term ‘you’ and ‘client’ refers to the subscriber of the Services on the Website. The RA provides the Research Services subject to the notices, terms, and conditions set forth in these Terms. By accepting these Terms when you subscribe to the Research Services, you provide your consent to abide by these Terms.

Most Important Terms and Conditions (MITC)

[Forming part of the Terms and Conditions for providing research services]

  1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
  2. The fee charged by RA to the client will be subject to the maximum amount prescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).
    Note:
    • SEBI's current cap on fee is Rs 1,51,000/- per annum per family of client for all research services of the RA.
    • The fee limit does not include statutory charges.
    • The fee limits do not apply to a non-individual client / accredited investor.
  3. RA may charge fees in advance if agreed by the client. Such advance shall not exceed the period stipulated by SEBI; presently it is one quarter. In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for the unexpired period.
  4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
  5. The RA is required to abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASB from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
  6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
  7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
  8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgement and assessment of the conclusions contained in the research report.
  9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
  10. For any grievances,
    • Step 1: the client should first contact the RA using the details on its website or following contact details:
      Customer care: [email protected]
      Grievance officer: [email protected], ATTN: Srikanth Meenakshi
      Compliance officer: [email protected], ATTN.: Bhavana Acharya
      Principal officer: [email protected], ATTN.: Vidya Bala
    • Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
    • Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in
  11. Clients are required to keep contact details, including email id and mobile number/s updated with the RA at all times.
  12. The RA shall never ask for the client’s login credentials and OTPs for the client’s Trading Account, Demat Account, and Bank Account. Never share such information with anyone including RA.

By browsing, viewing, using the Website and subscribing to the Research Services provided therein you consent to and agree to comply with these Terms and Conditions of subscription (“Terms”).

The RA reserves the right to change or modify the Website, the contents thereof and these Terms at any time. All modifications to these Terms & Conditions will be posted on the Website and will become effective immediately upon such posting. Changes once made will be communicated to the client. Continued use of the Website shall be construed as acceptance of the revisions to the Terms by conduct.

The following terms and conditions include but are not limited to minimum mandatory terms and conditions to clients as stipulated by SEBI.

1. Availing the research services

By accepting delivery of the research service, the client confirms that he/she has elected to subscribe to the research service of the RA at his/her sole discretion. The RA confirms that Research Services shall be rendered in accordance with the applicable provisions of the SEBI RA Regulations.

2. Obligations on RA

The RA shall be bound by the SEBI Act and all the applicable rules and regulations of SEBI, including the RA Regulations and relevant notifications of Government, as may be in force, from time to time.

3. Client Information and KYC

The client shall furnish all such details in full as may be required by the RA in its standard form with supporting details, if required, as may be made mandatory by Research Analyst Administration and Supervisory Body(RAASB)/SEBI from time to time. RA shall collect, store, upload and check KYC records of the clients with KYC Registration Agency (KRA) as specified by SEBI from time to time.

4. Standard Terms of Service

The consent of client shall be taken on the following understanding:

“I / We have read and understood the terms and conditions applicable to a research analyst as defined under regulation 2(1)(u) of the SEBI (Research Analyst) Regulations, 2014, including the fee structure.

I/We are subscribing to the research services for our own benefits and consumption, and any reliance placed on the research report provided by research analyst shall be as per our own judgement and assessment of the conclusions contained in the research report.

I/We understand that –

  1. Any investment made based on the recommendations in the research report are subject to market risk.
  2. Recommendations in the research report do not provide any assurance of returns.
  3. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report.”

The declaration of the RA is as follows:

  1. We are duly registered with SEBI as an RA pursuant to the SEBI (Research Analysts) Regulations, 2014 and our registration details are: registration no SEBI INH200008653, with registration date 19th August, 2021
  2. We have the registration and qualifications required to render the services contemplated under the RA Regulations, and the same are valid and subsisting;
  3. Research analyst services provided by us do not conflict with or violate any provision of law, rule or regulation, contract, or other instrument to which it is a party or to which any of its property is or may be subject;
  4. The maximum fee that may be charged by the RA is ₹1.51 lakhs per annum per family of client. Our current fee structure, the term and duration of our subscription for our Research Services, can be viewed on our website here: https://primeinvestor.in/prime-pricing
  5. The recommendations provided by us as part of the Research Services do not provide any assurance of returns.

5. Consideration and mode of payment

The client shall duly pay to the RA the agreed fees for the services that RA renders to the client and statutory charges, as applicable. Such fees and statutory charges shall be payable through the specified manner and mode(s)/ mechanism(s).

The payment of fees shall be through a mode that shows traceability of funds. Such modes include but are not limited to credit cards/debit cards/ UPI/ net banking or any other mode specified by SEBI from time to time. However, the fees shall not be in cash.

6. Risk factors

  1. Investments are subject to market risk. Investing or trading in financial products involves risk. Past performance of the recommendation is not an indication of future returns. Past performance of the RA is not an indicator of future performance. Past performance of the security is not an indication of future returns.
  2. There are no assurances or guarantees that the objectives of any investment in financial products will be achieved.
  3. The names of financial products mentioned herein do not in any manner indicate their prospects or returns. The performance in the equity may be adversely affected by the performance of individual companies, changes in the market place and industry specific and macro-economic factors.
  4. The performance of the investments/ products recommended by the RA are subject to a wide range of risks, including but not limited to: performance of the respective companies, changes in equity and debt market conditions, micro and macro factors and forces affecting equity and debt markets, general levels of interest rates and interest rate risk, credit risk, liquidity risk, reinvestment risk, economic slowdown, volatility & illiquidity of the stocks, risks associated with trading volumes, liquidity and settlement systems in equity and debt markets and/or such other circumstance beyond the control of the RA or any of its Associates.
  5. Other risk factors include that may affect the performance of the investments/ products recommended by the RA include but are not limited to economic policies, changes of Government and its policies, acts of God, acts of war, civil disturbance, sovereign action and /or such other acts/ circumstance beyond the control of the RA or any of its Associates.
  6. The recommendations provided by the RA as part of its Research Services may not be suitable to all categories of investors.
  7. The client should read all scheme and security related documents carefully before investing.
  8. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

7. Conflict of interest

The RA shall adhere to the applicable regulations/ circulars/directions specified by SEBI from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

General disclosures: PrimeInvestor Financial Research Pvt Ltd (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200008653). PrimeInvestor Financial Research Pvt. Ltd., its employees, directors or agents, do not have any material adverse disciplinary history as on the date of publication of this report.

Restrictions on trading: To ensure no conflict of interest, the RA declares as follows:

  1. Personal trading activities of the individuals employed as research analysts shall be monitored, recorded and subject to a formal approval by the directors or compliance officer of PrimeInvestor Financial Research Private Limited.
  2. Research analysts employed by PrimeInvestor Financial Research Private Limited or their associates or relatives shall not:
    • Deal/ trade in stocks recommended/ tracked by the research analyst within 30 days before and five days after the publication of a research report;
    • Deal/ trade in securities that the research analyst reviews in a manner contrary to the given recommendation;
    • Purchase or receive securities of the issuer before the issuer's initial public offering, if the issuer is principally engaged in the same types of business as companies that the research analyst follows or recommends.

Disclosures with respect to Research and Recommendations Services:

  1. The RA or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation.
  2. The RA, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its Research Services or investment information.
  3. The Research Analysts who have prepared the research reports that form part of the Research Services (“Research Analyst”) certify that all of the views expressed in the research report accurately reflect their views about the subject company or subject security.
  4. The RA or directors or employees or Research Analyst certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
  5. The Research Analyst has not served as director, officer or employee in the subject company, AMC or insurance company of the mutual fund or insurance policy that is the subject of this report, or company whose bonds, NCDs, fixed deposits or other savings products that is the subject of this report.
  6. The Research Analyst or their relatives do not have any known direct or indirect material conflict of interest including long/short positions in the subject company.
  7. The Research Analyst may hold investments in the stocks, mutual fund schemes, bonds, fixed deposits, insurance policies, or other products that are the subject of the recommendations provided as part of the Research Services. The Research Analyst certifies that they will not act in a manner contrary to their views on these securities except in the event of significant news or event or change in personal financial circumstances and without formal approval from the directors of PrimeInvestor Financial Research Pvt. Ltd. or the compliance officer.
  8. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of the Research Services. Such conflict of interest shall be disclosed to the client as and when they arise.
  9. The RA or its directors or its employee or its associates have not managed or co-managed the public offering of any company. The RA or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. The RA or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. The RA or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation.
  10. The subject company of its research recommendations was not a client of the RA or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided.
  11. The RA or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.

PrimeInvestor Financial Research Pvt. Ltd., its Associates, the Research Analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies)? – NO

8. Termination of service and refund of fees:

The RA may terminate or suspend rendering of Research Services to the client in the following circumstances:

  1. On account of suspension/cancellation of registration of RA by SEBI. In case of suspension of certificate of registration of the RA for more than 60 (sixty) days or cancellation of the RA registration, RA shall refund the fees, on a pro rata basis for the period from the effective date of cancellation/ suspension to end of the client’s subscription period.
  2. The RA voluntarily chooses to terminate its Research Service. In the event of such termination of the Research Service, the RA shall refund the fees, on a pro rata basis for the period from the date of such termination of research service to end of the client’s subscription period.

9. Grievance redressal and dispute resolution:

Any grievance related to:

  1. nonreceipt of research report, or
  2. missing pages or inability to download the entire report, or
  3. any other deficiency in the research services provided by RA

shall be escalated promptly by the client to the person/employee designated by RA, in this behalf as under:

Name: Bhavana Acharya
Designation: Director & Compliance Officer, PrimeInvestor Financial Research Pvt Ltd
Email: [email protected]

The RA shall be responsible to resolve grievances within 7 (seven) business working days or such timelines as may be specified by SEBI under the RA Regulations.

RA shall redress grievances of the client in a timely and transparent manner. Any dispute between the RA and his client may be resolved through arbitration or through any other modes or mechanism as specified by SEBI from time to time.

If the client is not satisfied with the response of the RA, he/she can lodge his/her grievances with SEBI at scores.sebi.gov.in. Alternatively, the client may also write to any of the offices of SEBI. For any queries, feedback or assistance, please contact SEBI Office on Toll Free Helpline at 1800 22 7575 / 1800 266 7575

Details on grievances are available on the Website as follows: https://primeinvestor.in/ra-grievance/

10. Additional clauses:

Scope of the Research Service: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Services are not meant to be tailor-made or customized solutions that specifically apply to each client based on his/her risk profile.

The RA never guarantees the returns on the recommendation provided. Investor shall take note that investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The RA shall not be responsible for any loss to the Investors.

This service is not directed for access or use by anyone in a country, especially the USA, Canada or the European Union countries, where such use or access is unlawful or which may subject PrimeInvestor Financial Research Pvt Ltd or its affiliates to any registration or licensing requirement.

The Research Service, including recommendations, research reports, updates, and other information will be accessible through the RA’s website https://primeinvestor.in only. Such recommendations and updates will not be provided over phone calls.

Fees: Our current fee structure, the term and duration of our subscription for our Research Service, can be viewed on our website: https://primeinvestor.in/prime-pricing. Eligibility for any discounts is ascertained at the time the client subscribes. Any such discount and its tenure shall be at the discretion of the RA.

Subscription and access to content services fall under the purview of Goods and Services Tax (GST) as per the current indirect taxation policy, Government of India. Unless otherwise indicated, prices stated on our website are exclusive of applicable GST, any applicable value added tax (VAT) or other sales taxes. We are a business-to-consumer (B2C) service provider and we do not commit to provide any input tax credit on GST charged on subscription to our Research Service.

We may change the Subscription Fees and charges then in effect, or add new fees or charges which will take effect at the end of the client’s subscription period, by giving notice in advance and an opportunity to cancel renewal of the subscription.

Subscription Access & Renewal: Subscription to the Website commences immediately on the realisation of payment of the Subscription Fees. Subscriptions are set to be renewed automatically at the end of the subscription period.

Unless the client notifies us before the end of his/her subscription period, or the client cancels the auto-renewal mandate within the period specified by law, that the client does not wish to renew his/her subscription, the client’s subscription will renew for the period defined by the client’s subscription plan. We will charge the subscription using the same payment method that you previously used.

Although the client may notify to us his/her intention to his/her subscription, such notice will only take effect at the end of his/her then current subscription period, and he/she will not receive a refund other than as set out under Clause 8 in these Terms.

The client may notify us of his/her wish to cancel his/her subscription by sending an email to [email protected]. The client must provide at least 5 business days advance notice for this to be implemented.

Refunds: There can be no cancellation and refund of subscription fee paid once the subscription is active, other than as stated in Clause 8 of these Terms. If the client is entitled to a refund as specified under Clause 8 of these Terms, the RA will credit that refund to the card or other payment method used by the client to submit payment, unless it has expired - in which case the RA will contact the client to proceed with the refund. If we do issue a refund or credit due to circumstances outside the obligations specified under Clause 8, we are under no obligation to issue the same or a similar refund in the future.

General disclaimers: The recommendations made herein in the Research Services are expression of views and/or opinions and should not be deemed or construed to be advice for the purpose of purchase or sale of any security, nor a solicitation or offering on any investment/ trading opportunity on behalf of the company, AMC, insurance company, or issuer of security referred to herein.

The content and research reports generated by the RA does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities.

The information/ opinion/ views mentioned in research reports or by the RA are not meant to serve as a professional guide to the client or recipients of this Report. The research report, recommendation, or any other content published by the RA do not assure or guarantee any minimum or fixed returns to the client or recipients of the reports/ recommendations/ content.

Use of this information is at the client’s own risk. The client must make his/ her own investment decisions based on his/her specific investment objective and financial position and using such independent advisors as he/she believes necessary. The services rendered by the RA are on a best-effort basis. All information in the content or research report of the RA is provided on an as is basis. Information is believed to be reliable but the RA does not warrant its completeness or accuracy and expressly disclaim all warranties and conditions of any kind, whether express or implied.

While due care has been taken to ensure that the disclosures, information, and opinions given are fair and reasonable, PrimeInvestor Financial Research Pvt Ltd and/or none of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information/ opinions/ views contained in the research report and recommendations that form part of the Research Service, and/or mails, social media or notifications issued by PrimeInvestor Financial Research Pvt Ltd or any other agency appointed/authorised by PrimeInvestor Financial Research Pvt Ltd. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

Any agreements, transactions or other arrangements made between the client and any third party named on (or linked to from) the Website are at your own responsibility and entered into at your own risk. Any information that you receive via the Website, whether or not it is classified as “real time”, may have stopped being current by the time it reaches you. Market price information may be rounded up/down and therefore may not be entirely accurate.

The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research Services before onboarding.

History, present business and background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services.

Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made thereunder against the Research Analyst relating to Research Analyst services.

Details of the RA's associates: No associates.

Usage of Website Content: This Website is controlled and operated by the RA. All material, including research reports, recommendations, portfolios, ratings, lists of financial products, illustrations, statements, opinions, views, photographs, products, images, artwork, designs, text, graphics, logos, button icons, images, audio and video clips and software (collectively, “Content”) are protected by copyrights, trademarks and other intellectual property rights that are owned and controlled by the RA or by other parties that have licensed their material to us.

Except where otherwise agreed in writing with the RA, material on the Website is solely for the client’s personal, non-commercial use. Except as provided below, the client must not copy, reproduce, republish, upload, post, transmit or distribute such material in any way, including by e-mail or other electronic means and whether directly or indirectly and the client must not assist any other person to do so.

Without the prior written consent of the RA, modification of the materials, use of the materials on any other web site or networked computer environment or use of the materials for any purpose other than personal, non-commercial use is a violation of the copyrights, trademarks and other proprietary rights, and is prohibited. Any use for which the client receives any remuneration, whether in money or otherwise, is a commercial use for the purposes of these Terms.

The client may occasionally distribute a copy of a research report, or a portion of the same, from the Website in non-electronic form to a few individuals without charge, provided the client includes all copyright and other proprietary rights notices in the same form in which the notices appear, original source attribution, and the phrase “Used with permission from PrimeInvestor Financial Research Pvt. Ltd.”

While the client may occasionally download and store research reports or information from the Website for his/her personal use, he/she may not otherwise provide others with access to the same. The foregoing does not apply to any sharing functionality we provide through the Website that expressly allows the client to share Content or links to Content with others. In addition, the client may not use Content he/she has downloaded for personal use to develop or operate an automated trading system or for data or text mining.

The client agrees not to rearrange or modify the Content available through the Website. The client agrees not to display, post, frame, or scrape the Content for use on another website, app, blog, product or service, except as otherwise expressly permitted by these Terms. You agree not to create any derivative work based on or containing the research products and Content. The framing or scraping of or in-line linking to the Services or any Content contained thereon and/or the use of webcrawler, spidering or other automated means to access, copy, index, process and/or store any Content made available on or through the Services other than as expressly authorized by us is prohibited.

The client further agrees to abide by exclusionary protocols (e.g., Robots.txt, Automated Content Access Protocol (ACAP), etc.) that may be used in connection with the Research Services. The client may not access parts of the Research Services to which he/she is not authorized, or attempt to circumvent any restrictions imposed on your use or access of the Services.

As a general rule, the client may not use the Content, including without limitation, any Content made available through one of our RSS Feeds, in any commercial product or service, without our express written consent.

The client may not create apps, extensions, or other products and services that use our Content without our permission. The client may not aggregate or otherwise use our Content in a manner that could reasonably serve as a substitute for a subscription to the Website.

The client may not access or view the Services with the use of any scripts, extensions, or programs that alter the way the Services are displayed, rendered, or transmitted to you without our written consent.

The client agrees not to use the Services for any unlawful purpose. We reserve the right to terminate or restrict the client's access to the Website if, in our opinion, the client's use of the Services may violate any laws, regulations or rulings, infringe upon another person's rights or violate these Terms.

Prohibited content: The Website includes comments sections, blogs and other interactive features that allow interaction among clients and between clients and the RA. We call the information posted by or contributed by users “Contributed Content.” In the course of availing of the Research Services or uploading any post or comment on the Website, the client shall not post any Contributed Content that (i) contains nude, semi-nude, sexually suggestive photos, (ii) tends or is likely to abuse, harass, threaten, impersonate or intimidate other users of the Website and/or Research Services, (iii) is lascivious or appeals to the prurient interest or if its effect is such as to tend to deprave and corrupt persons who are likely to use or have access to the Website and/or Services, or (iv) otherwise violates, is prohibited or restricted by applicable law, rule or regulation, is offensive or illegal or violates the rights of, harms or threatens the safety of other users of the Website and/or Services (collectively “Prohibited Content”).

We reserve the right to cease to provide the client with the Research Services or access to the Website, or terminate your subscription, with immediate effect and without notice and liability, for violating these Terms, applicable law, rules or regulations and reserves the right to remove Prohibited Content which is in violation of these Terms, or is otherwise abusive, illegal or disruptive. The determination of whether any content constitutes Prohibited Content, violates these Terms, or is otherwise abusive illegal or disruptive, is subject to the sole determination of the Firm.

Changes to Research Services: We are constantly endeavouring to improve the quality of Research Services provided to our clients. Due to this, the form and nature of the Research Services provided may change from time to time without any prior notice to the client. We reserve the right to introduce and initiate new features, functionalities, components to the Website and/or Research Services and/or change, alter, modify, or discontinue existing ones without any prior notice to the client.

Warranty and liability disclaimer: The Website, Research Services, and all the materials and services, included on or otherwise made available to the client through this Website is provided by the RA on an “as is” and “as available” basis without any representation or warranties, express or implied except otherwise specified in writing. Without prejudice to the foregoing paragraph, the RA does not warrant that:

  • This Website and/or Research Services will be constantly available, or available at all;
  • The information on this Website or provided through the Research Services is complete, true, accurate or not misleading; or
  • The quality of any products, services, information, or other material that you obtain through the Website or Services will meet your expectations.

The RA, to the fullest extent permitted by law, disclaims all warranties, whether express or implied, including the warranty of merchantability, fitness for particular purpose and non-infringement. The RA makes no warranties about the accuracy, reliability, completeness, or timeliness of the Website, Research Services, Content, Contributed Content, Services, software, text, graphics and links.

The RA does not warrant that this Website, Research Services, information, content, materials, or any other material included on or otherwise made available to you through this Website, their servers, or electronic communication sent by the RA are free of viruses or other harmful components.

Nothing on this Website constitutes, or is meant to constitute, advice of any kind.

Indemnification: The client:

  1. Represents, warrants and covenants that no materials of any kind provided by him/her will:
    1. Violate, plagiarise, or infringe upon the rights of any third party, including copyright, trademark, privacy or other personal or proprietary rights; or
    2. Contain libellous, Prohibited Content or other unlawful material;
  2. Hereby agree to indemnify, defend and hold harmless the RA and all of the RA’s officers, directors, owners, agents, customers/clients, information providers, affiliates, licensors and licensees (collectively, the “Indemnified Parties”) from and against any and all liability and costs, including, without limitation, reasonable advocate’s fees, incurred by the Indemnified Parties in connection with any claim arising out of any breach by the client of these Terms or the foregoing representations, warranties and covenants. The client shall cooperate as fully as reasonably required in the defence of any such claim. The RA reserves the right, at its own expense, to assume the exclusive defence and control of any matter subject to indemnification by the client.

Applicable law: This Website, including the Content and Contributed Content and information contained herein, and the provision of Research Services shall be governed by the Securities and Exchange Board of India, laws of the Republic of India and the courts of Chennai, India which shall retain exclusive jurisdiction to entertain any proceedings in relation to any disputes arising out of the same. As such, the laws of India shall govern any transaction completed using this Website.

Information gathered and tracked: Information submitted or collected on the Website or pursuant to the use of the Services is stored in a database. Specifically, we store the username, name, e-mail address, contact number, as submitted or collected on our Website or through the provision of the Research Services. We may use such information to send out occasional promotional materials, including alerts on new Services available, or other promotional and marketing material relating to our clients and customers.

In accordance with the Information Technology Act 2000, the name and the details of the Grievance Officer at PrimeInvestor is provided below:

Mr. Srikanth Meenakshi
PrimeInvestor Financial Research Pvt. Ltd., Registered office: 659, 4th Avenue, D-Sector, Anna Nagar Western Extension, Chennai 600 101.
Email: [email protected]

11. Mandatory notice:

Clients shall be requested to go through Do’s and Don’ts while dealing with RA as specified in SEBI master circular no. SEBI/HO/MIRSD-POD-1/P/CIR/2024/49 dated May 21, 2024 or as may be specified by SEBI from time to time.

12. Optional Centralised Fee Collection Mechanism:

SEBI has operationalized a centralized fee collection mechanism for IA and RA. Under this mechanism, clients shall pay fees to IAs/RAs through a designated platform/portal administered by a recognized Administration and Supervision body. This is an optional mechanism for the registered entities. At this time, PrimeInvestor has opted out of this fee collection mechanism. Therefore, all subscription payments for the Research Services will be through the modes as specified in Clause 5 of these Terms.

Enter the OTP sent to (Edit)
By doing this you agree to our terms & conditions
Didn't receive OTP? Resend

Have an account?
Login To Your Account
OR
Don’t have an account ? Register for free